GlassScriptPhysician profile
Himani Sharma
NPI 1811373657
$3,557.02
in general payments reported to CMS, 2019-2025
34 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $156 · 2022: $69.38 · 2023: $576 · 2024: $1,271 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,103 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150 · Education: $78.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,103.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
| Education | $78.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $461.58 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.79 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $268.62 | 2024-2025 | Tepezza, Evenity |
| Insulet Corporation | $230.23 | 2022-2024 | Omnipod |
| Beta Bionics, INC. | $218.62 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sanofi-Aventis U.S. LLC | $201.76 | 2021-2025 | |
| Corcept Therapeutics | $179.42 | 2024-2025 | Korlym |
| Lilly USA, LLC | $163.57 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Xeris Pharmaceuticals, INC. | $146.32 | 2021-2025 | Gvoke Hypopen |
| Averitas Pharma INC. | $133.66 | 2024-2025 | Qutenza |
| Radius Health, INC. | $114.49 | 2024-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $113.04 | 2023-2024 | Strensiq |
| Tandem Diabetes Care, INC. | $93.89 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $72.18 | 2025 | Cequr Simplicity |
| Neurocrine Biosciences, INC. | $69.58 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $69.11 | 2024-2025 | Minimed 780g, Intellis Adaptivestim |
| Soleno Therapeutics, INC. | $62.42 | 2025 | Vykat Xr |
| Recordati_rare_diseases_inc. | $62.30 | 2025 | Isturisa |
| Ascendis Pharma Endocrinology INC | $52.30 | 2025 | Yorvipath |
| Kyowa Kirin, INC. | $51.90 | 2023-2025 | Crysvita |
| Novartis Pharmaceuticals Corporation | $51.80 | 2025 | |
| Dexcom, INC. | $51.79 | 2023 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $47.52 | 2024-2025 | Xyosted |
| Abbvie INC. | $46.60 | 2024 | |
| Abbott Laboratories | $40.38 | 2021-2024 | Freestyle Libre 3 |
| Ascensia Diabetes Care US INC. | $32.66 | 2023 | |
| Esperion Therapeutics, INC. | $31.59 | 2024-2025 | Nexletol |
| Sequel Med Tech, LLC | $28.95 | 2025 | Twiist |
| Horizon Therapeutics Plc | $20.91 | 2023 | Tepezza |
| Ibsa Pharma INC. | $20.90 | 2025 | Licart, Tirosint, Flector |
| Chiesi USA, INC. | $19.73 | 2024 | Mycapssa |
| Astrazeneca Pharmaceuticals LP | $17.02 | 2021 | |
| Chiasma, INC. | $15.05 | 2021 | |
| Zealand Pharma US, INC. | $13.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Himani Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.